FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)

View source ↗

Summary

FDA approved a supplemental application for VIMPAT (lacosamide) from UCB, Inc., resulting in a labeling update/expanded use for the anticonvulsant.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy
• Partial-onset Seizures

Drugs mentioned

• Vimpat (lacosamide)

Snippet

SUPPL AP for VIMPAT (LACOSAMIDE)